Product Description
a propriety magnesium formulation being studied as a treatment for acute spinal cord injury (SCI)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: N/A
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Acorda
Company Location: ARDSLEY NY 10502
Company CEO: Ron Cohen
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Spinal Cord Injuries
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
AC105 | P2 |
Terminated |
Spinal Cord Injuries |
2015-02-01 |